The development of COVID-19 vaccines around the world has made significant progress since the coronavirus pandemic began. Countries are rapidly collaborating on vaccine research, development and distribution to control the spread of the virus. One of the first vaccines to receive approval was Pfizer-BioNTech, which uses mRNA technology. This vaccine was proven to have high efficacy, reaching 95%, and received emergency approval in many countries at the end of 2020. Apart from Pfizer, Moderna also developed an mRNA vaccine which showed similar results. These two vaccines play an important role in the global vaccination strategy. In addition, viral vector-based vaccines such as AstraZeneca and Janssen (Johnson & Johnson) are also being developed. AstraZeneca uses adenovirus as a vector, with an effectiveness of around 76%. The Janssen vaccine requires only one dose, making it a practical option for a wide range of populations. Both are key components in vaccination programs, especially in countries with limited resources. The Sinovac and Sinopharm vaccines from China are also widely used, especially in Asian and African countries. Sinovac, using an inactivated virus, shows efficacy of around 50-80%. Although lower compared to mRNA vaccines, their accessibility and lower cost make them a popular choice in some developing countries. Furthermore, research continues to develop booster vaccines and achieve better protection, especially against new variants of the virus. Vaccines such as Novavax have also emerged as an alternative. Research shows that a combination of different types of vaccines can improve the immune response and provide broader protection. Distribution of the vaccine is also a big challenge. With complex logistics systems and the need for low-temperature storage for mRNA vaccines, low-income countries have difficulty accessing the vaccines. The COVAX program, spearheaded by WHO, aims to ensure vaccines are available equitably in all countries. Through COVAX, more than 1.4 billion vaccine doses have been distributed to more than 140 countries by 2023. Mass vaccination and public education are also important to increase immunization rates. Many countries have achieved high vaccination rates thanks to effective information campaigns. However, challenges such as vaccine refusal and disinformation must still be addressed. Social media platforms play a role in spreading the right information about the benefits of vaccination. Research and innovation in developing a COVID-19 vaccine continues. Technological breakthroughs, such as DNA-based vaccines, offer new hope for the future of vaccination. This progress shows that the world can unite in responding to a global health crisis. As the world gradually recovers from the impact of the pandemic, a successful COVID-19 vaccine is an important step in re-establishing normal life.